Radiation before CAR T-Cell therapy: a new hope for tough lymphoma?
NCT ID NCT05800405
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests whether giving radiation to all active cancer spots before CAR T-cell infusion can help control large B-cell lymphoma that has come back or not responded to treatment. Nine adults with relapsed or refractory lymphoma will receive targeted radiation during the wait for their CAR T-cells. The goal is to see if this bridging approach is safe and feasible, potentially improving treatment outcomes with minimal added toxicity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- external beam radiation therapy
- What this could lead to
- If successful, this approach could make CAR T-cell therapy more effective for patients with aggressive lymphoma that has returned or not responded to treatment.
- What could go wrong
- This is a very early, small feasibility study with only 9 participants, so results may not apply broadly. Radiation may cause side effects or fail to improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Multi-Drug combo outsmart resistant lymphoma?
- Could adjusting chemo doses boost CAR T-Cell success against tough lymphoma?
- Radiation boost may supercharge CAR T-Cell therapy against tough lymphoma
- New combo approach aims to boost CAR-T success in tough lymphoma
- New combo attack on lymphoma shows promise in early trial
- New trial aims to bring targeted lymphoma drugs to minority patients